ExodusPoint Capital Management’s Summit Therapeutics SMMT Stock Holding History

ExodusPoint Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.86M	Buy	+256,255	New	+$4.14M	0.04%	449
2025 Q4	–	Sell	-23,513	Closed	-$486K	–	2032
2025 Q3	$486K	Buy	+23,513	New	+$570K	0.01%	1191
2023 Q3	–	Sell	-25,775	Closed	-$65K	–	2112
2023 Q2	$65K	Buy	+25,775	New	+$47K	﹤0.01%	1769
2021 Q2	–	Sell	-93,533	Closed	-$549K	–	2763
2021 Q1	$549K	Sell	93,533 -92,311	-50%	-$596K	0.01%	1279
2020 Q4	$873K	Buy	+185,844	New	+$787K	0.01%	931

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ExodusPoint Capital Management's SMMT Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 256,255 shares worth $4.86M. The stake represents 0.04% of the portfolio and ranks #449 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in SMMT as recently as Q3 2025.

ExodusPoint Capital Management first reported a position in SMMT in Q4 2020 and has held it in 5 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

ExodusPoint Capital Management held 256,255 shares of Summit Therapeutics worth $4.86M as of Q1 2026.
Summit Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
Summit Therapeutics made up 0.04% of ExodusPoint Capital Management's portfolio in Q1 2026, its #449 holding.
ExodusPoint Capital Management first reported a position in Summit Therapeutics in Q4 2020 and has held it in 5 quarters since.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.